比较全腺、外周带与移行区前列腺特异性抗原密度对临床显著前列腺癌的检测
回顾性纳入2019年1月至2020年12月连续接受前列腺MRI后行系统穿刺(联合或不联合靶向穿刺)的551例患者,比较全腺、移行区与外周带PSAD对临床显著前列腺癌的诊断效能。单变量分析显示全腺与移行区PSAD的AUC优于外周带PSAD,多变量分析(纳入年龄与5α-还原酶抑制剂治疗)中移行区PSAD预测临床显著前列腺癌的AUC优于全腺与外周带PSAD。
要点
- 单变量分析中全腺PSAD与外周带PSAD检测任何前列腺癌的AUC分别为0.71与0.56,临床显著前列腺癌为0.71与0.56。
- 多变量分析中移行区PSAD预测临床显著前列腺癌AUC为0.77,优于全腺PSAD的0.75(P=0.02)。
- 变量重要性分析提示处方5α-还原酶抑制剂治疗可能对临床显著前列腺癌有保护作用。
核心结论
- 全腺PSAD与移行区PSAD检测临床显著前列腺癌优于外周带PSAD。
- 在纳入关键协变量后,移行区PSAD可能优于全腺PSAD。
研究设计与样本
- 回顾性研究,纳入2019年1月至2020年12月连续接受前列腺MRI后行系统穿刺(联合或不联合靶向穿刺)的患者共551例,中位年龄66岁(IQR 61-72)。
- PSA水平于影像检查前抽取,体积估计由MRI经人工智能软件辅助得出。
- 诊断效能采用逻辑回归与内部验证的ROC曲线下面积(AUC)评估。
诊断标准与关键数值
- 单变量分析:全腺PSAD检测任何前列腺癌与临床显著前列腺癌的AUC均为0.71,移行区PSAD均为0.72,外周带PSAD分别为0.51与0.56。
- 多变量分析(纳入年龄与5α-还原酶抑制剂治疗):移行区PSAD预测临床显著前列腺癌AUC为0.77,全腺PSAD为0.75(P=0.02),外周带PSAD为0.67(P<0.001)。
临床应用与阅片要点
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: Compare the diagnostic performance of whole-gland prostate-specific antigen density (wgPSAD) to zonal volume-adjusted prostate-specific antigen density (PSAD) for predicting prostate cancer in patients who underwent a prostate magnetic resonance imaging (MRI) followed by prostate biopsy.
MATERIALS AND METHODS: A retrospective study of consecutive patients who underwent prostate MRI followed by systematic biopsy with or without targeted biopsy between January 2019 and December 2020 was performed. Whole-gland (wgPSAD), transition-zone prostate-specific antigen density (tzPSAD), and peripheral-zone prostate-specific antigen density (pzPSAD) were calculated using prostate-specific antigen (PSA) levels drawn before imaging, and volume estimates were derived from MRI using artificial intelligence (AI) software assistance. Diagnostic performance was assessed using logistic regression and estimating internally validated receiver operating characteristic area under the characteristic (AUC) curves.
RESULTS: A total of 551 patients with a median age of 66 years (interquartile range [IQR]: 61-72) were included. The univariable analysis demonstrated superior AUC for wgPSAD (AUC: 0.71 and 0.71) and tzPSAD (AUC: 0.72 and 0.72) compared to pzPSAD (AUC: 0.51 and 0.56) for any cancer and clinically significant prostate cancer (csPCa). The multivariable analysis including age and 5α-reductase inhibitor therapy demonstrated a superior AUC of tzPSAD for predicting csPCa (AUC: 0.77 vs 0.75; P=0.02) compared to both wgPSAD and pzPSAD (AUC: 0.77 vs 0.67; P<0.001). Variable importance analysis suggested prescribed 5α-reductase inhibitor therapy may be protective against csPCa.
CONCLUSION: wgPSAD and tzPSAD are superior to pzPSAD for the detection of csPCa. When accounting for key covariates, tzPSAD may be superior to wgPSAD.
引用
- Cochran RL, Mercaldo ND, Nakrour N, et al. Comparing conventional, peripheral, and transition zone prostate-specific antigen densities for the detection of clinically significant prostate cancer. Clin Radiol. 2025. PMID: 41420971. doi:10.1016/j.crad.2025.107189
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。